Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Guardant Health reported its second quarter 2026 financial results highlighting broad-based growth across all key segments: Oncology, Biopharma & Data, and Screening.</li><li>Total revenue reached $335 million, up 44% year-over-year, with Oncology revenue at $219 million (38% growth), Biopharma & Data at $61 million (9% growth), and Screening revenue rising significantly to $53 million from $15 million a year ago.</li><li>The company demonstrated accelerated test volume growth, particularly in its Oncology business, where volumes increased 63% year-over-year to approximately 104,000 tests, supported by expansions in products such as Guardant360 Liquid (over 30% volume growth), Guardant360 Tissue, and Reveal, the latter growing over 100% driven by minimal residual disease (MRD) and therapy monitoring adoption.</li></ul>

Guardant Health reported its second quarter 2026 financial results highlighting broad-based growth across all key segments: Oncology, Biopharma & Data, and Screening.Total revenue reached $335 million, up 44% year-over-year, with Oncology revenue at $219 million (38% growth), Biopharma & Data at $61 million (9% growth), and Screening revenue rising significantly to $53 million from $15 million a year ago.The company demonstrated accelerated test volume growth, particularly in its Oncology business, where volumes increased 63% year-over-year to approximately 104,000 tests, supported by expansions in products such as Guardant360 Liquid (over 30% volume growth), Guardant360 Tissue, and Reveal, the latter growing over 100% driven by minimal residual disease (MRD) and therapy monitoring adoption.

Guardant Health’s 70 Million-Patient Breakthrough — Shield Is Scaling Fast!